Could nafamostat or gabexate prevent the post endoscopic retrograde cholangiopancreatography pancreatitis?
There was no meaningful difference among the gabexate, nafamostat and placebo group.
Traf5 negatively regulates NAFLD/NASH and related metabolic dysfunctions by blocking Jnk1 activity, which represents a potential therapeutic target for obesity-related metabolic disorders.